Results 11 to 20 of about 37,371 (257)
Dabigatran (October 2011) [PDF]
Cleveland Clinic Journal of Medicine, 2011 Van Mitchell Smith
openalex +4 more sources
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran [PDF]
Pharmaceutics, 2022 Dabigatran (DAB) is an orally administered thrombin inhibitor. Both DAB and its main metabolite dabigatran acylglucuronide (DABG) have established anticoagulant effects. Here, we aimed to compare the relative anticoagulant effects of DABG and DAB in humans.
Jong-Min Kim +7 more
openaire +3 more sources
American Journal of Neuroradiology, 2011 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
L, Murphy, L, Lawler, E C, Kavanagh
openaire +4 more sources
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]
, 2012 Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Bohmann, Ferdinand +6 more
core +14 more sources
American Journal of Neuroradiology, 2012 Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less ...
J, Comin, D F, Kallmes
openaire +2 more sources
Dabigatran (October 2011) [PDF]
Cleveland Clinic Journal of Medicine, 2012 Readers comment on the oral anticoagulant dabigatran (October 2011), and screening for cervical cancer (November 2011).
Patricio A. Pazmiño
openalex +4 more sources
Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation [PDF]
, 2013 OBJECTIVE: In clinical trials of dabigatran and rivaroxaban for stroke prevention in atrial fibrillation (AF), drug eligibility and dosing were determined using the Cockcroft-Gault equation to estimate creatine clearance as a measure of renal function ...
Ashman, N +6 more
core +3 more sources
The Discovery of Dabigatran Etexilate [PDF]
Frontiers in Pharmacology, 2013 Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is caused by an excessive stimulation of coagulation. Thrombin is a key serine protease in the coagulation cascade and numerous efforts have been made to develop safe and effective orally active direct thrombin inhibitors (DTIs).
Henning Priepke +6 more
openaire +4 more sources
Dabigatran etexilate tetrahydrate [PDF]
Acta Crystallographica Section E Structure Reports Online, 2012 In the title compound, C34H41N7O5·4H2O (systematic name: ethyl 3-{[2-({4-[(Z)-amino-(hexyl-oxycarbonyl-imino)-meth-yl]anilino}meth-yl)-1-meth-yl-benzimidazole-5-carbon-yl]pyridin-2-yl-amino}-propano-ate tetra-hydrate), the benzene and pyridine rings form dihedral angles of 5.4 (1) and 43.8 (1)°, respectively, with the benzimidazole mean plane.
Zhi-Qiang Cai +4 more
openaire +4 more sources
Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran [PDF]
, 2015 © Otsui et al. 2015BACKGROUND: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required; however, a
Gorog, Diana A +8 more
core +2 more sources